Corton Capital’s INmune Bio INMB Stock Holding History

Corton Capital’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-76,143	Closed	-$410K	–	498
2024 Q3	$410K	Buy	76,143 +55,598	+271%	+$395K	0.2%	96
2024 Q2	$181K	Buy	+20,545	New	+$203K	0.1%	394

Other funds holding INMB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Praetorian PR Rincon, Puerto Rico $275M AUM 84.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DIG

Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Corton Capital's INMB Position: Q4 2024 in Review

Corton Capital sold out of INmune Bio (INMB) in Q4 2024, closing a stake of 76,143 shares — an estimated $410K sold.

Corton Capital first reported a position in INMB in Q2 2024 and held it in 2 quarters. The position peaked at $410K in Q3 2024. 73 funds tracked by Wall St. Rank hold INMB as of Q4 2024.

Corton Capital reported no remaining INmune Bio position as of Q4 2024 after selling out during the quarter.
Corton Capital sold 76,143 INmune Bio shares in Q4 2024, an estimated $410K.
Corton Capital first reported a position in INmune Bio in Q2 2024 and held it in 2 quarters.
Corton Capital's INmune Bio position peaked at $410K in Q3 2024.
73 funds tracked by Wall St. Rank held INmune Bio as of Q4 2024.

Based on Corton Capital's 13F filing for Q4 2024, filed 14 Feb 2025.